Isolated nucleic acid molecules encoding human squalene synthase proteins, and related products and processes

ABSTRACT

The present invention provides amino acid sequences of human squalene synthase proteins and nucleic acid sequences encoding these squalene synthase proteins. The present invention provides isolated squalene synthase proteins and encoding nucleic acid molecules, vectors and host cells containing these nucleic acid molecules, and processes for producing the squalene synthase proteins.

FIELD OF THE INVENTION

The present invention is in the field of enzyme proteins that are related to the synthase enzyme subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides a novel alternative splice form of a squalene synthase enzyme and nucleic acid molecules encoding the novel splice form, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Many human enzymes serve as targets for the action of pharmaceutically active compounds. Several classes of human enzymes that serve as such targets include helicase, steroid esterase and sulfatase, convertase, synthase, dehydrogenase, monoxygenase, transferase, kinase, glutanase, decarboxylase, isomerase and reductase. It is therefore important in developing new pharmaceutical compounds to identify target enzyme proteins that can be put into high-throughput screening formats. The present invention advances the state of the art by providing novel human drug target enzymes related to the synthase subfamily.

Synthases

The novel human protein, and encoding gene, provided by the present invention is related to the family of synthases in general and squalene synthases (also known by such names as squalene synthetases and farnesyl-diphosphate farnesyltransferases) in particular. Furthermore, the protein of the present invention may be a novel isoform of the protein/gene provided in Genbank gi4758350. Specifically, the protein/cDNA of the present invention differs from the art-known protein of gi4758350 in that the fourth exon is spliced out of the protein/cDNA of the present invention (see the amino acid sequence alignments in FIG. 2).

Squalene synthase is important for catalyzing the first specific step in the biosynthesis of cholesterol, which is the conversion of trans-farnesyldiphosphate to squalene. Squalene synthase regulates this major control point in sterol, as well as isoprene, biosynthesis in eukaryotes (Robinson et al., Mol Cell Biol 1993 May;13(5):2706-17). Squalene synthase thus occupies a critical regulatory position in cholesterol synthesis (Schechter et al., Genomics 1994 Mar. 1;20(1):116-8). Furthermore, the squalene synthase gene has been associated with Rec syndrome (Patterson et al., Am. J. Hum. Genet. 57: A91 only, 1995).

Loss of promoter activity and response to sterols has been localized to a 69-bp region that is positioned 131 bp upstream from the transcription start site; this region contains a sterol regulatory element-1, which is found in other sterol regulated genes, and two possible NF1 binding sites (Guan et al., Biol. Chem. 270: 21958-21965, 1995).

For a further review of squalene synthases, see McKenzie et al., J Biol Chem 1992 Oct. 25;267(30):21368-74; Summers et al., Gene 1993 Dec. 22;136(1-2Che):185-92; Jiang et al., J Biol Chem 1993 Jun. 15;268(17):12818-24; and Soltis et al., Arch Biochem Biophys 1995 Feb. 1;316(2):713-23.

Due to their importance in cholesterol biosynthesis, novel human squalene synthase proteins/genes, such as provided by the present invention, are valuable as potential targets for the development of therapeutics to treat cholesterol-related diseases/disorders such as cardiovascular diseases. Furthermore, SNPs in squalene synthase genes, such as provided by the present invention, may serve as valuable markers for the diagnosis, prognosis, prevention, and/or treatment of cholesterol-related diseases/disorders such as cardiovascular diseases.

Using the information provided by the present invention, reagents such as probes/primers for detecting the SNPs or the expression of the protein/gene provided herein may be readily developed and, if desired, incorporated into kit formats such as nucleic acid arrays, primer extension reactions coupled with mass spec detection (for SNP detection), or TaqMan PCR assays (Applied Biosystems, Foster City, Calif.).

Enzyme proteins, particularly members of the synthase enzyme subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of enzyme proteins. The present invention advances the state of the art by providing previously unidentified human enzyme proteins, and the polynucleotides encoding them, that have homology to members of the synthase enzyme subfamily. These novel compositions are useful in the diagnosis, prevention and treatment of biological processes associated with human diseases.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human enzyme peptides and proteins that are related to the synthase enzyme subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate enzyme activity in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver.

DESCRIPTION OF THE FIGURE SHEETS

FIG. 1 provides the nucleotide sequence of a cDNA sequence that encodes the enzyme protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver.

FIG. 2 provides the predicted amino acid sequence of the enzyme of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIG. 3 provides genomic sequences that span the gene encoding the enzyme protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in FIG. 3, SNPs were identified at 55 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a enzyme protein or part of a enzyme protein and are related to the synthase enzyme subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of a novel human synthase enzyme alternative splice form, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode this novel enzyme splice form, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the enzyme of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known enzyme proteins of the synthase enzyme subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known synthase family or subfamily of enzyme proteins.

SPECIFIC EMBODIMENTS

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the enzyme family of proteins and are related to the synthase enzyme subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the enzyme peptides of the present invention, enzyme peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the enzyme peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, “substantially free of cellular material” includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language “substantially free of chemical precursors or other chemicals” includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the enzyme peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated enzyme peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. For example, a nucleic acid molecule encoding the enzyme peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the enzyme peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The enzyme peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a enzyme peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the enzyme peptide. “Operatively linked” indicates that the enzyme peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the enzyme peptide.

In some uses, the fusion protein does not affect the activity of the enzyme peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant enzyme peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A enzyme peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the enzyme peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the enzyme peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology. Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds. Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)), using a NWS gapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the enzyme peptides of the present invention as well as being encoded by the same genetic locus as the enzyme peptide provided herein. The gene encoding the novel enzyme of the present invention is located on a genome component that has been mapped to human chromosome 8 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a enzyme peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the enzyme peptide as well as being encoded by the same genetic locus as the enzyme peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel enzyme of the present invention is located on a genome component that has been mapped to human chromosome 8 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme of the present invention. SNPs were identified at 55 different nucleotide positions, including a non-synonymous coding SNP at nucleotide position 8031 (protein position 45). The change in the amino acid sequence caused by this SNP is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. Some of these SNPs that are located outside the ORF and in introns may affect gene transcription.

Paralogs of a enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the enzyme peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the enzyme peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the enzyme peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the enzyme peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a enzyme peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., Science 247:1306-1310 (1990).

Variant enzyme peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as enzyme activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

The present invention further provides fragments of the enzyme peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a enzyme peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the enzyme peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the enzyme peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in enzyme peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as Proteins—Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (Meth. Enzymol. 182: 626-646 (1990)) and Rattan et al. (Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

Accordingly, the enzyme peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature enzyme peptide is fused with another compound, such as a compound to increase the half-life of the enzyme peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature enzyme peptide, such as a leader or secretory sequence or a sequence for purification of the mature enzyme peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a enzyme-effector protein interaction or enzyme-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, enzymes isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver. A large percentage of pharmaceutical agents are being developed that modulate the activity of enzyme proteins, particularly members of the synthase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to enzymes that are related to members of the synthase subfamily. Such assays involve any of the known enzyme functions or activities or properties useful for diagnosis and treatment of enzyme-related conditions that are specific for the subfamily of enzymes that the one of the present invention belongs to, particularly in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the enzyme, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the enzyme protein.

The polypeptides can be used to identify compounds that modulate enzyme activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the enzyme. Both the enzymes of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the enzyme. These compounds can be further screened against a functional enzyme to determine the effect of the compound on the enzyme activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the enzyme to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the enzyme protein and a molecule that normally interacts with the enzyme protein, e.g. a substrate or a component of the signal pathway that the enzyme protein normally interacts (for example, another enzyme). Such assays typically include the steps of combining the enzyme protein with a candidate compound under conditions that allow the enzyme protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the enzyme protein and the target, such as any of the associated effects of signal transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant enzymes or appropriate fragments containing mutations that affect enzyme function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) enzyme activity. The assays typically involve an assay of events in the signal transduction pathway that indicate enzyme activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the enzyme protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the enzyme can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the enzyme can be assayed. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver.

Binding and/or activating compounds can also be screened by using chimeric enzyme proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate then that which is recognized by the native enzyme. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the enzyme is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the enzyme (e.g. binding partners and/or ligands). Thus, a compound is exposed to a enzyme polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble enzyme polypeptide is also added to the mixture. If the test compound interacts with the soluble enzyme polypeptide, it decreases the amount of complex formed or activity from the enzyme target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the enzyme. Thus, the soluble polypeptide that competes with the target enzyme region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the enzyme protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of enzyme-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a enzyme-binding protein and a candidate compound are incubated in the enzyme protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the enzyme protein target molecule, or which are reactive with enzyme protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the enzymes of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of enzyme protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the enzyme pathway, by treating cells or tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. These methods of treatment include the steps of administering a modulator of enzyme activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the enzyme proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the enzyme and are involved in enzyme activity. Such enzyme-binding proteins are also likely to be involved in the propagation of signals by the enzyme proteins or enzyme targets as, for example, downstream elements of a enzyme-mediated signaling pathway. Alternatively, such enzyme-binding proteins are likely to be enzyme inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a enzyme protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a enzyme-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the enzyme protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a enzyme-modulating agent, an antisense enzyme nucleic acid molecule, a enzyme-specific antibody, or a enzyme-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The enzyme proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. The method involves contacting a biological sample with a compound capable of interacting with the enzyme protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered enzyme activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (Clin. Exp. Pharmacol. Physiol. 23(10-11):983-985 (1996)), and Linder, M. W. (Clin. Chem. 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the enzyme protein in which one or more of the enzyme functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and enzyme activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. Accordingly, methods for treatment include the use of the enzyme protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab′)₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the enzyme proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or enzyme/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver. Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the enzyme peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nuleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a enzyme peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the enzyme peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an “isolated” nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5 KB, 4 KB, 3 KB, 2 KB, or 1 KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an “isolated” nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5′ and 3′ non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the enzyme peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the enzyme proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5′ to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel enzyme of the present invention is located on a genome component that has been mapped to human chromosome 8 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme of the present invention. SNPs were identified at 55 different nucleotide positions, including a non-synonymous coding SNP at nucleotide position 8031 (protein position 45). The change in the amino acid sequence caused by this SNP is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. Some of these SNPs that are located outside the ORF and in introns may affect gene transcription.

As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C., followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As illustrated in FIG. 3, SNPs were identified at 55 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5′ noncoding regions, the coding region, and 3′ noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. The gene encoding the novel enzyme of the present invention is located on a genome component that has been mapped to human chromosome 8 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in enzyme protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a enzyme protein, such as by measuring a level of a enzyme-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a enzyme gene has been mutated. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate enzyme nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the enzyme gene, particularly biological and pathological processes that are mediated by the enzyme in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver. The method typically includes assaying the ability of the compound to modulate the expression of the enzyme nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired enzyme nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the enzyme nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for enzyme nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the enzyme protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of enzyme gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of enzyme mRNA in the presence of the candidate compound is compared to the level of expression of enzyme mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate enzyme nucleic acid expression in cells and tissues that express the enzyme. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for enzyme nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the enzyme nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, bladder, and liver.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the enzyme gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in enzyme nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in enzyme genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the enzyme gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the enzyme gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a enzyme protein.

Individuals carrying mutations in the enzyme gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme of the present invention. SNPs were identified at 55 different nucleotide positions, including a non-synonymous coding SNP at nucleotide position 8031 (protein position 45). The change in the amino acid sequence caused by this SNP is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. Some of these SNPs that are located outside the ORF and in introns may affect gene transcription. The gene encoding the novel enzyme of the present invention is located on a genome component that has been mapped to human chromosome 8 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077-1080 (1988); and Nakazawa et al., PNAS 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., Nucleic Acids Res. 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a enzyme gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant enzyme gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv. Chromatogr. 36:127-162 (1996); and Griffin et al., Appl. Biochem. Biotechnol. 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985)); Cotton et al., PNAS 85:4397 (1988); Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285:125-144 (1993); and Hayashi et al., Genet. Anal. Tech. Appl. 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., Nature 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the enzyme gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme of the present invention. SNPs were identified at 55 different nucleotide positions, including a non-synonymous coding SNP at nucleotide position 8031 (protein position 45). The change in the amino acid sequence caused by this SNP is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. Some of these SNPs that are located outside the ORF and in introns may affect gene transcription.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control enzyme gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of enzyme protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into enzyme protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of enzyme nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired enzyme nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the enzyme protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in enzyme gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired enzyme protein to treat the individual.

The invention also encompasses kits for detecting the presence of a enzyme nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that the enzymes of the present invention are expressed in humans in the placenta, T-cells from T-cell leukemia, fetal brain, pancreas, Burkitt lymphoma, and bladder, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in the liver. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting enzyme nucleic acid in a biological sample; means for determining the amount of enzyme nucleic acid in the sample; and means for comparing the amount of enzyme nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect enzyme protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein “Arrays” or “Microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5′, or 3′, sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The “pairs” will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the enzyme proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the enzyme gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the enzyme of the present invention. SNPs were identified at 55 different nucleotide positions, including a non-synonymous coding SNP at nucleotide position 8031 (protein position 45). The change in the amino acid sequence caused by this SNP is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. Some of these SNPs that are located outside the ORF and in introns may affect gene transcription.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified enzyme gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, E. coli, Streptomyces, and Salmonella typhimurium. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enteroenzyme. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990)119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example E. coli. (Wada et al., Nucleic Acids Res. 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., S. cerevisiae include pYepSec1 (Baldari, et al., EMBO J. 6:229-234 (1987)), pMFa (Kurjan et al., Cell 30:933-943(1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J. 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as enzymes, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with enzymes, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a enzyme protein or peptide that can be further purified to produce desired amounts of enzyme protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the enzyme protein or enzyme protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native enzyme protein is useful for assaying compounds that stimulate or inhibit enzyme protein function.

Host cells are also useful for identifying enzyme protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant enzyme protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native enzyme protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a enzyme protein and identifying and evaluating modulators of enzyme protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the enzyme protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the enzyme protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, enzyme protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo enzyme protein function, including substrate interaction, the effect of specific mutant enzyme proteins on enzyme protein function and substrate interaction, and the effect of chimeric enzyme proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more enzyme protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

                   #             SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 6 <210> SEQ ID NO 1 <211> LENGTH: 1606 <212> TYPE: DNA <213> ORGANISM: Human <400> SEQUENCE: 1 gcgcctgggg accgcagagg tgagagtcgc gcccgggagt ccgccgcctg cg #ccaggatg     60 gagttcgtga aatgccttgg ccaccccgaa gagttctaca acctggtgcg ct #tccggatc    120 gggggcaagc ggaaggtgat gcccaagatg gaccaggact cgctcagcag ca #gcctgaaa    180 acttgctaca agtatctcaa tcagaccagt cgcagtttcg cagctgttat cc #aggcgctg    240 gatggggaaa tgcgcaacgc agtgtgcata ttttatctgg ttctccgagc tc #tggacaca    300 ctggaagatg acatgaccat cagtgtggaa aagaaggtcc cgctgttaca ca #actttcac    360 tctttccttt accaaccaga ctggcggttc atggagagca aggagaagga tc #gccaggtg    420 ctggaggact tcccaacgta ctgccactat gttgctgggc tggtcggaat tg #gcctttcc    480 cgtcttttct cagcctcaga gtttgaagac cccttagttg gtgaagatac ag #aacgtgcc    540 aactctatgg gcctgtttct gcagaaaaca aacatcatcc gtgactatct gg #aagaccag    600 caaggaggaa gagagttctg gcctcaagag gtttggagca ggtatgttaa ga #agttaggg    660 gattttgcta agccggagaa tattgacttg gccgtgcagt gcctgaatga ac #ttataacc    720 aatgcactgc accacatccc agatgtcatc acctaccttt cgagactcag aa #accagagt    780 gtgtttaact tctgtgctat tccacaggtg atggccattg ccactttggc tg #cctgttat    840 aataaccagc aggtgttcaa aggggcagtg aagattcgga aagggcaagc ag #tgaccctc    900 atgatggatg ccaccaatat gccagctgtc aaagccatca tatatcagta ta #tggaagag    960 atttatcata gaatccccga ctcagaccca tcttctagca aaacaaggca ga #tcatctcc   1020 accatccgga cgcagaatct tcccaactgt cagctgattt cccgaagcca ct #actccccc   1080 atctacctgt cgtttgtcat gcttttggct gccctgagct ggcagtacct ga #ccactctc   1140 tcccaggtaa cagaagacta tgttcagact ggagaacact gatcccaaat tt #gtccatag   1200 ctgaagtcca ccataaagtg gatttacttt ttttctttaa ggatggatgt tg #tgttctct   1260 ttattttttt cctactactt taatccctaa aagaacgctg tgtggctggg ac #ctttagga   1320 aagtgaaatg caggtgagaa gaacctaaac atgaaaggaa agggtgcctc at #cccagcaa   1380 cctgtccttg tgggtgatga tcactgtgct gcttgcggct catggcagag ca #ttcagtgc   1440 cacggtttag gtgaagtcgc tgcatatgtg actgtcatga gatcctactt ag #tatgatcc   1500 tggctagaat gataattaaa agtatttaat ttgaaaaaaa aaaaaaaaaa aa #aaaaaaaa   1560 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa    #               1606 <210> SEQ ID NO 2 <211> LENGTH: 374 <212> TYPE: PRT <213> ORGANISM: Human <400> SEQUENCE: 2 Met Glu Phe Val Lys Cys Leu Gly His Pro Gl #u Glu Phe Tyr Asn Leu  1               5   #                10   #                15 Val Arg Phe Arg Ile Gly Gly Lys Arg Lys Va #l Met Pro Lys Met Asp             20       #            25       #            30 Gln Asp Ser Leu Ser Ser Ser Leu Lys Thr Cy #s Tyr Lys Tyr Leu Asn         35           #        40           #        45 Gln Thr Ser Arg Ser Phe Ala Ala Val Ile Gl #n Ala Leu Asp Gly Glu     50               #    55               #    60 Met Arg Asn Ala Val Cys Ile Phe Tyr Leu Va #l Leu Arg Ala Leu Asp 65                   #70                   #75                   #80 Thr Leu Glu Asp Asp Met Thr Ile Ser Val Gl #u Lys Lys Val Pro Leu                 85   #                90   #                95 Leu His Asn Phe His Ser Phe Leu Tyr Gln Pr #o Asp Trp Arg Phe Met             100       #           105       #           110 Glu Ser Lys Glu Lys Asp Arg Gln Val Leu Gl #u Asp Phe Pro Thr Tyr         115           #       120           #       125 Cys His Tyr Val Ala Gly Leu Val Gly Ile Gl #y Leu Ser Arg Leu Phe     130               #   135               #   140 Ser Ala Ser Glu Phe Glu Asp Pro Leu Val Gl #y Glu Asp Thr Glu Arg 145                 1 #50                 1 #55                 1 #60 Ala Asn Ser Met Gly Leu Phe Leu Gln Lys Th #r Asn Ile Ile Arg Asp                 165   #               170   #               175 Tyr Leu Glu Asp Gln Gln Gly Gly Arg Glu Ph #e Trp Pro Gln Glu Val             180       #           185       #           190 Trp Ser Arg Tyr Val Lys Lys Leu Gly Asp Ph #e Ala Lys Pro Glu Asn         195           #       200           #       205 Ile Asp Leu Ala Val Gln Cys Leu Asn Glu Le #u Ile Thr Asn Ala Leu     210               #   215               #   220 His His Ile Pro Asp Val Ile Thr Tyr Leu Se #r Arg Leu Arg Asn Gln 225                 2 #30                 2 #35                 2 #40 Ser Val Phe Asn Phe Cys Ala Ile Pro Gln Va #l Met Ala Ile Ala Thr                 245   #               250   #               255 Leu Ala Ala Cys Tyr Asn Asn Gln Gln Val Ph #e Lys Gly Ala Val Lys             260       #           265       #           270 Ile Arg Lys Gly Gln Ala Val Thr Leu Met Me #t Asp Ala Thr Asn Met         275           #       280           #       285 Pro Ala Val Lys Ala Ile Ile Tyr Gln Tyr Me #t Glu Glu Ile Tyr His     290               #   295               #   300 Arg Ile Pro Asp Ser Asp Pro Ser Ser Ser Ly #s Thr Arg Gln Ile Ile 305                 3 #10                 3 #15                 3 #20 Ser Thr Ile Arg Thr Gln Asn Leu Pro Asn Cy #s Gln Leu Ile Ser Arg                 325   #               330   #               335 Ser His Tyr Ser Pro Ile Tyr Leu Ser Phe Va #l Met Leu Leu Ala Ala             340       #           345       #           350 Leu Ser Trp Gln Tyr Leu Thr Thr Leu Ser Gl #n Val Thr Glu Asp Tyr         355           #       360           #       365 Val Gln Thr Gly Glu His     370 <210> SEQ ID NO 3 <211> LENGTH: 40090 <212> TYPE: DNA <213> ORGANISM: Human <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(40090) <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 3 tatttattcc taattaaatg gggaggaaag tctttgaaga ggaacctcta ct #ttactttt     60 tataccgtca tggctggaaa ctaagttttt aagatttttc tggggttccc tt #ggccgagg    120 tggggagtgg gagggctgtc cagtggtagg gacttaggat ttttagttta ca #gtagtagg    180 ggaaacactc tgtaatctaa tacataagta aatgatgtat tagaatatgg ta #aatatagg    240 caagtagacc cccactggga ttagcagtgg tggaaatgtg agagagggca aa #caggtggg    300 tctagatgag gtgtgagcag actcgagggg cacaggagtt agtcaagcca gt #atctgggg    360 gatagtgcag gaatagtgaa cagctagaca aaaagtccta gggccagaga aa #gcaaaagc    420 ataagagatg gaggccagag aggtaatctg ggtggaaggc tgcagcctct ca #ggatccct    480 ataggtgctt tggcttttgt tggagagaca ctgaacagct ttgggcagtg aa #cgtacctg    540 acaggtttcc tgtttgtttt tgagatgaag tctcgctctt gtcccccagg ct #ggagtgca    600 atagcgcgat ctcagctcac tgcaacctct gcctcctgtg ttcaagcgat tc #tcctgcct    660 cagcctccca ggtagctggg attataggcg cctgccacca tgcctggcta at #ttttgtat    720 ttttagtaga gacgcagttt cagcatgttg gccaggctgg tcttgaactc ca #gacctcag    780 gtgatccgcc cgccttggcc tcccaaagtg ctgggattac aggcgtgagc ca #ccgcgctc    840 ggctagacct gacaggtttt aaaaggatta ctggttgctg tgttaaaaca ga #ctgcagga    900 tggcttaggt agccagtagg tttttttttt ttttggagac gtagtcttgc tc #tgttggcc    960 tggctggagt gcagcggtgt catcttggct cactgcaaac tccgcttccc gg #gttcaagt   1020 gattctcctg cctcagcctc cggagtagtt gggactacag gcgcccacca cc #acactcgg   1080 cttttttgta tttttagtag agacgggttt caccatgttg gccaggatgg tc #tcgatctc   1140 ttgacctcgt gatccacccg ccttggcctc ccaaagtgtt gcgattacag gc #gtgagcca   1200 ccacgcctgg acgggtagcc agtagtttct agggctggag agatctagga tg #agagaagt   1260 ttccacattc ctgttacagg ctctctaagg cttcagctcc tttttctagg ac #taagctgg   1320 atctcaagta aacactagag agggggcagc tgaagctcca ggagtgtgtg gg #gctccctg   1380 gggctggatg gcggtggcgg gcaggcgagc tgggctgtgc tcgggtgtgt ta #cagtaaag   1440 acgcccagct tggcgctggc ccggcctttt cacggtttta ggctctacag ag #agcggctg   1500 cagagctcac ccggctggca ggagccaccg aggccggaca cgtgggcgac tt #attgacca   1560 agtggggagg aagcagcccc gcactgctct cccgactgcg gaccaccgtt gg #gctcatgc   1620 gcatcataag ccccaccgcc tcacctccag tccccacagc gttcgcgctc cc #agccgggg   1680 taagcggaag aaaacaaagg cccggctcca tcagggcacc aatcccgctc gt #cggcctct   1740 ttctcggcct ccaatgagct tctagggtgt tatcacgcca gtctccttcc gc #gactgatt   1800 ggccggggtc ttcctagtgt gagcggccct ggccaatcag gcgcccgtca gc #ccacccca   1860 cgaggccgca gctagccccg ctggcggccg aggccggttg aagtgggcgg ag #cggcgggc   1920 ggggcgtcgc cgtactaggc ctgccccctg tccggccagc ccctcgaagc ac #ctactcca   1980 caggtccagc cggccggtga gcgcctgggg accgcagagg tgagagtcgc gc #ccgggagt   2040 ccgccgcctg cgccaggatg gagttcgtga aatgccttgg ccaccccgaa ga #gttctaca   2100 acctggtgcg cttccggatc gggggcaagc ggaaggtgat gcccaagatg ga #ccaggtgg   2160 gccgagcctc cctgcttgcc cggggcgggg aaggagctcg ctgggccggc ct #cagggcct   2220 gagcggccgg gcccggatct ggggcaaggg gcgcggcgag cagggccgac gc #ctgggtgt   2280 tcccgtcccc ctttcctcga gccttccccc tgtagggccc gggtggacgc gg #ccgtcctg   2340 gctgacctgt ccctgccccc gcaagccgcc ctgggcatga gcgacttttg cg #tggttccc   2400 ggtggttgcg ctccccgttt cgtcccctcc gtgagcatcg gcgcttaccg gt #attttaac   2460 ccgagggtta cacatctgag gcaatgtggg tgggttacgc gggagaggac ga #gtgagttt   2520 tttggtaagc ggaatgaact atgcagataa catcacatga aggccgtttc tg #gaatgaag   2580 tctgactcct ccagtttcac cacctcttcc ggagctctcc ccgccttgct gc #cttccatc   2640 gcttcatcct cggtgcttcc tgagttttaa aatcgcctat ctacgcttcc aa #gttccaat   2700 gagttatcta acgtctatgg attagctagg tggttggtgg aaggtcagaa ct #tggtttta   2760 cttagatttt tatctgcctc atgcctgtac tatttgttta atgaatgcat ag #gaggtgtt   2820 tttattccaa caagaaaatt attcgtacgc gattattgaa tgaatagaca aa #ttcagcca   2880 agttcttctg gtctggacca gcctggctga tttctgtaac ttttttgggc ca #acaggaca   2940 gtagcaaatg tgactcaggc cgaggcttga taggtgcctg aacatcggag tc #tttctttc   3000 agtgtccatg tgcttcagta aacacactag aaaataaatt tctggttttt gt #ccccagta   3060 gactacaccc tcatttggtg ttatttttca cgtgctatct ttaatacagg ta #catccttc   3120 agtctatttg tagaacattc agttttcttc atcttttctt tgccggtgct ac #attatttg   3180 aattattttg ctacagaata acttctatta tttgatatgg cagatgtcac tt #tttatatt   3240 tagatatagc attcatttat ttaacaaata tttgacgacc agttgtatat ca #gatagtgt   3300 tctaggtgct ggaggtacaa cagtgaacaa gctaggtgaa gaccttgatt tt #ataaaact   3360 tactttttag tggaagagag acaatttaaa aaagcgaatg tacagttttt ca #cgtggaga   3420 aaagcactgc agaggaagat actagcaggg caagggatct gagtgcagtc ag #acctcatt   3480 tgggtccaga cttcattcct ctatgtctct ttcctttcta cagaaagact gt #tagagaaa   3540 atggtagcat tggtttcctg ttgggaggga aagtgggtgg tcatggtaag tg #ggtagaga   3600 aagacttcac agtatactgt ttttgtacat tttgagtttt tttaaaagcg ag #acttgagc   3660 tattctagct ctgataatat ggtgcagtat ttgttatgtt agttgtagtc tt #tctgggca   3720 gtttttacat ccccatgagc cgttaaaaaa atacctgaac ctttaattag gg #gaaataaa   3780 ttggaaaaat acatttccct tcacttaaca ttatcttagt ttctcttttt tt #tttttttt   3840 ttttttgaga tggagtcttg ctctgttacc caggctggag tgcagtggtg gc #gggacctc   3900 agctagatgc agcctccgcc tcctgggttc aagcaattct cctgcctcag cc #tgctgagt   3960 agctgggatt acaggcacct gccactacgc ccggctgatt ttttggtatt tt #tagtagag   4020 acggggtttc accatgttgg cgaggctggt tttgaactct tgacctcaag tg #atctgctc   4080 gccttggtct cccaaagtgc taggattaca ggcgtgagcc actgcacccg gc #cttttttt   4140 tttttttttt gagggggggg tctcactcca tcgtccaggc tagaatgctg tg #gcctgaac   4200 atgactcact ccagttttga cttccttggc tgaagccatc ctcccacctc gg #cttcctga   4260 tcccgagtag ctgggactcc aggcacgtgt caccaatgca tggctaattt tt #aaattttt   4320 ttgtagacac aatgtctcgc tgcattgccc aggctggtct tgaactcctg ag #ctcaagcg   4380 attttcccac ctcagccttc aaagtgctgg gattacaggt gtgagccact gc #acccaacc   4440 agtttctctc tgcaaactag ggaaaaaatt tacgcttagc agatattgag gg #ctgattat   4500 ttctatcaca gaagcatttg gctatagaat ttcagggttt agtaaacttg at #ttacactg   4560 aatttttagg tgcatatcag taaatctacg ggcatatgcc gcctgcaagt tg #tgtggcat   4620 cacccaaaag ccgagagtaa tggaaagagc aggctgttag taatcaggca ga #tctggctc   4680 ctgtccaatc taaatcctgt tatttagact aatatcttaa gtctgttatt aa #gtccgatt   4740 tctgacgcta ttaagttagg tgaacaacct tggtaactta acctctgaac ca #cagttact   4800 tcatctgtaa aatagggatg tatgtatggt aacgattttt taaccacaac tt #cccaactc   4860 taagatggtc tgaaaagaat tttttgagtg tttggctcag aatcacttgg ca #gcaaaacc   4920 tgacttgaag ttgaggcttc attcatccca cttagtatat tcaaatgttt tg #ctaaagaa   4980 ataattatga ggtgctactt cacactgact agggttgtat atgcatttta tt #gcctattt   5040 tctaaaacac taaaaatgct aaattctgcc ccaggtcttg ccacagatgt tt #cagtggac   5100 tatgggcctg tgagacctta aagggttgat tgagtaagga tcacaggtga tg #tccgcatt   5160 gtgcttggca tggagttaag tgcttgataa atggtggtta tcaatctgat ta #tgtaaatt   5220 tatgtaaatt cagttctcaa gtttgtggtt tttttcccct cctggagaaa tc #tattctat   5280 tttaaagtga ggaaggctcc gtggagggct ggtagctggt agctgttcac tt #gtggaact   5340 ttcagcctga ggctggagcc ccttcctggg agtctggtct tgtcgtcttc ct #gaccaccc   5400 ccacaccctt cctctaaatt ccctccatcc ctgtttttct cccgcttgcg ag #cttttggg   5460 agtgtgctga atctcagact gcaatagata aacccaagag ggacaggcac ca #gtagcctg   5520 agcttgcttt ctcccctggc tcatgggaat caagcagtag aaatttttag tg #agtgttgt   5580 tttccatagt atgcttacta gttgtgtctt cctgttttgt tcttggtgat tt #gaagaaac   5640 ctgtttacaa ggtaagggac tgaaacaaat aggtgacagg aaaaagagca gc #aggggtac   5700 gagctggagg agtaagtggc ttggcttgct ctctttcaga atggagggct gt #atggaaag   5760 gaggggtagt gttcttgaag agtgttgggg tttaaatcta gggggaccgt gt #cttggcat   5820 tgattgaaac tcctggctta acatcacccc gaaactgtta gttggactga ac #atgacatt   5880 tggcagtgca gttaaaaaca cttcctgctg tagcctggta atggtcaggc ta #tgtgaaga   5940 gctgctctgg agctcagtcc agagcgggta ttctgtttct ttcactctga aa #tcctgcct   6000 ctcgatattt tgagaaggaa ggagttggtg aattgtttta aaatcctcga tg #aatgtctt   6060 catttattca tgacaccact tctgaatata tttatgtgcc agacgctgaa gt #ttactaat   6120 attatggtgc ccagtaaata cttgttttta ctaatatttt ttatggcaat aa #aatgactt   6180 tttcaggatt atgtgattta aaagattgac ccttttggca aaatacgtat tc #atgatagg   6240 aaatatatac aacatagttc acttaaacct cccaccagag cccagggttc ac #tgttacca   6300 ttctgaagtg actggaattt cctagaagtg gatatgccat atttttttaa cc #actcctat   6360 tggatatttg ttttttattt ttttgagatg gggtcccact ctgcagtgta ca #atatcata   6420 gttcactgta acgtgtatct cttgggctca agcgatcctc cccacctcag cc #tccctgag   6480 tagctagtct tcagtagcta gactataggt gggcgccacc acagctggct tt #ttaaaaaa   6540 ttttttatga acacgaggtc tcactatgtt gcccaggctg ccctcaaact cc #tgggctca   6600 agtgattctc ccaccttggc cttccgaagt gcagggatta taggcgtgcg cc #actgcacc   6660 cggccctgtt ggataaatga ttccagtctc tcccaaaaag aactgttgta ag #actgtggg   6720 gtgaggggag ggaagggaca aataggaacc cgccgtattt tccactccct gt #gggcctaa   6780 aactgctcta aaaaatagtc catgaaaaaa tacatagtac aaacagcaac tc #tttctgat   6840 atgcttgcat ttaaaatcag gctttttctc ccttttggaa aaacacagtc ct #tgtttgct   6900 ttagggaaga gtaaaggtca gtgcgctgca ttgcattaat ttcgaaggga aa #gatgagaa   6960 gacatcttga aaggaatggc tggctttcta gagaatagta gaggcttaat ag #gtgtcata   7020 gaaaaaccag ggttggacag tggtagtaaa acggcaaaac agattttatt ca #gaaaaact   7080 actgcagtaa gaggagagag acctcggtac agaactgctc cactgcgaat ac #aaagaaaa   7140 gtaggaattg atggcggggg agccggatgt cagtggatgg aaaattatta cg #aggaaaca   7200 caggggtgtg cattcttgct gaaggcaggc cagagttatc agacatcacc tg #agggatgg   7260 agggggatgt ggaacctaat cggctgtcta gggtgatcag atactgaagt tg #ggggattc   7320 tggtcaaatc aatttagcag gattcttggt aaaactgggc gatgcaaaga ca #gatgcgtt   7380 gagtacaaag tccaggcttt attgggaaga ggatttcagc ggagcccgag ta #gagtttgg   7440 tctagggaga ctctgtcact gggaggacga gcgagccgct cggaagtgcg ct #gggttctc   7500 ttagcggcca gtgggttctg gtgagaaggg caacagcggg aggaggcgcc gg #tgcggagc   7560 gggaggccgg gggcggggct gcggggctgc ggggcgggcc cgttgtgggt cg #gcccagcg   7620 cgtattcgag tagagggcga gcccgtcccg cctctcgtcg ggcgcttccc ag #atctgctt   7680 gagtctatgg aggaaaaact ccgcggggtc cgcgattccc atggccgcag cc #gcctgcgg   7740 caccaaggcc atggccctct tcaagcgcac cttggtgctg agtcccgccg cg #gcgcccag   7800 gggcccgggc gcaggcaccg ccccgcgggg ctgctgcttg cctcctgccg cc #tggccctg   7860 caaggactgg cctcggggag agggcggcag gctgtggagc cgcctgcccc ag #tcccagtc   7920 ccactcccac tcccactccc actcccactc ctgctcctcg acgtctccca cc #gccgtgtg   7980 tgttgtctgc ccgcaggact cgctcagcag cagcctgaaa acttgctaca ag #tatctcaa   8040 tcagaccagt cgcagtttcg cagctgttat ccaggcgctg gatggggaaa tg #cggtgagt   8100 gatggaggca gcgcctctgg cttggaggaa agcttgtccg ggacttttga gt #gtgttgga   8160 agctaccttt tgatatagcg ctcagcgttg cagcctcgtt gctgtggctt at #ccagaaca   8220 tagcccggcc ctacgtgttt actttagaaa gcccttccag gctctttgcc at #ctagtaga   8280 gtccctgcgg gcccagcctt tcagagaagg ggggggaggg ggtgatgttt at #taactttt   8340 tttagtcttg gcagctgaac ctgcctgtga gcaggtcgtg tatttctcgg ct #tcccttat   8400 ccaactttgc atttctattt ctagcatatt gggttgattc ttttgaagct gc #ctctgtgc   8460 acattacacc catgaactta gaccagttgc ctttatgtat gatcgtattt at #actgagaa   8520 gttactgtgt tttttgactt tcttttctat ttgctacata ttagttcggt ct #aaacgttt   8580 ggtcttctgg tctccatagt tctacattgg ttaaatgcaa ctcacttctg gg #agtagtgg   8640 tgacattcaa ctagtaggct ttttaataaa ctacagaagt tcattactct ca #tgtaagga   8700 aggaaaacta atgtaacttt cgttaagtat gaaaagcgtt ggatatcctt at #agttcttt   8760 agagttaagg gtgagatggg tttagaaagt ggccaggcac aagttatttt aa #aataaaaa   8820 atctttggct gtttgttcca atatattaat agttttccct tttttacagc aa #cgcagtgt   8880 gcatatttta tctggttctc cgagctctgg acacactgga agatgacatg ac #catcagtg   8940 tggaaaagaa ggtcccgctg ttacacaact ttcactcttt cctttaccaa cc #agactggc   9000 ggttcatgga gagcaaggag aaggatcgcc aggtgctgga ggacttccca ac #ggtgagtg   9060 gggttacgca tcttgtctac ggactgttgt gttcataatt gctaacgtgg tt #gtccggta   9120 gcctccatac atgtggagaa aggttaaata agcattctga gggcagcata at #gtgagggt   9180 taaaaactcc ggtagccaag actctgaagc caggctgcct gggttggaat ct #caaatctc   9240 ccacttacta aactgttggt tacttacaaa gactctctgt gcctcagttt ct #tcatctgt   9300 aaaatagggg taataataac acctacctca tggtattctg aggattcaaa ga #attaacgt   9360 aggtaatgct cttagaatgt tagctactgc tgttattatc agtattggaa gt #ccagtgtt   9420 tcttcctgtg ggaagacgca gtcaaatttt agtgttgtga aagattctca gg #ctagctca   9480 caaaagcctg ccgactgtat gatgcagcct acctgtaaca ctgctggcct ct #tgactacc   9540 cggagcctgg tagcatggga ctgctgctca cgatgggcag cagcctggca tg #ggggcggt   9600 gtctgttggc agctagggcg agcctctgcc acttcacctg tgatcctggg ca #agttcctt   9660 atctgctttg tgtctccgtc tcctcgtttg taaagttaga gctgagagga tt #aatttcgc   9720 acatataaag tacttagtgc ctggtacagg gtaagtattc tgtaagtatt ag #ctatttgg   9780 tctattttgt tggagtaaag tgggttatag ttaaaatcct aagattttta aa #gtccctca   9840 agttcacgtg gacatctgcc taggtcctac tatcctagaa ttcgcatgtc tt #atcacaca   9900 aataactgat tcttccatat cttataaata aaggtttgat ttagcaaagt ca #catgttgt   9960 gtaatagctc gaagaagccc tttttgtcca cagttgccag agcttttgga ga #acagtcct  10020 tatgttattg aaacaaacct aatctgtagc tgagttggga gggagctaag tg #gacagaga  10080 gtcctccacc caaacaaaag aatctttgat tcttgggcat aatgggagca at #atttaaaa  10140 aaaaaaaaaa aaaaaaaaaa ggaatgtttg gggaagactc ttgcggtgca aa #ggctgttt  10200 cagattgctg agatcagacc ttaagtacca aagcccaaat atagtacaac at #aatacaaa  10260 tgagaagaaa atagctgaag aataattcga gtttatacag tacaattcaa ga #gaagaaag  10320 aaaatttatg acgactagct gggtgagaat tagaactgta accctgggaa gg #tcctggtg  10380 atttgactct cacaggacac ctgatgacca gaggatgggt ttcctttgat gg #gaaatctg  10440 tggcgattca ttgatgggcc tctgaattct gctgaagcag aggaagtagt aa #taccccat  10500 ttataatgga agtgcattct cacttaaaaa caactaatat tattctagct gg #acctagcc  10560 tctagaaaca gccaaattac atttgacttg agtggattca taataattaa aa #aatttctg  10620 gggcatggga taaatgtgtt aggtattgct aagtcaaggc agccctatcc cc #tcagcaga  10680 agtgagggaa tatgaaagtg tgtgaatgct aacataattt tggggaatat cg #ccgtcaga  10740 tttccagatg atattccaac atgtttgtga aacttcagtg tcttcctgtg tt #catacagt  10800 gttccagtgg aaaaataatg cttagttctg gaaggtttca gatgtgaaca ct #gaactcat  10860 cgttttcttt tttgggtagt agagttagag attccatcct cttgaaagca ca #gttgcccc  10920 gggaagagta aaagggagca gaaggcgtaa gccaggcacg gctgttttca ct #gttgttca  10980 ccttttgtat ccttacgaat atgaagatgt actaagttgt gtgttttgcg tg #catatata  11040 attttaagct acttgagttg taggtccctc cagtctgtga ttcagtttga ga #tgggactg  11100 tatgggaatt aacagtgcct tgtcttctta agcagtgatt tgtgtatgtg ct #gatatagc  11160 tcagtatgtc tttgaaacca gttgtctggg gctaggcctg caatcagctt tt #ggctaaga  11220 ggtcccagga tggaacaagt agtgtgaaag aggactgata ccttggcctc ac #acacagta  11280 ctgctcttag actggggcaa gtgaaactcc tcacttcaga gtgccccatt ct #aggccccc  11340 tcactcccaa aggggtgagg gatcactggg gccatgggaa tgtgcttgtt ca #gctctcgt  11400 gggctctcct tctgtaccac gttctggaca tctggagttc cttgccccaa at #ccctgagc  11460 ccacgtctgc gtccgcacag tctatttcct aaggtcagtc catctcctcc ag #gtgggaac  11520 gtgccaccat tgactgtgcc cttgggcctg agtgatggcc aagggctgtg tt #ggggagtg  11580 ttgtggatgg atcctggcac cgagggctgg gatatcctct caaatgaatg tg #aggtgcct  11640 cccagtgctg gagagagcgg gattcaggaa gcagtggaag ggaagagcct gg #gatatggg  11700 gatcagctgt ctgtgccctg ctgcattctg gaataaaact ctgagggact aa #gaattcta  11760 aattcaaacc tgaatcaacc aggttgttac aaagataagt ttgtcagtgc ag #gaggatac  11820 aatatatttt acttaagtta ctagctcgat tgatcatttt taaattttta gc #tacatata  11880 gtatgtgggc ctccatttgt cctcttatcc caggccttgc agaatttagg aa #taagcctc  11940 aatacagtgt tctaacccag tgacttccgc ctcgatgtac agtagattga ac #ctgatcct  12000 ttatacttta gtgatcatta gttgatacca gttcaagtca ggctttctag aa #atctcatt  12060 gtatgttagg ggttcgatta gagtacagtc atgcatcact taatgaatgg cc #acaggata  12120 cattctgaga aacgcattga tagatgattt catcattctg tgaacatcat ag #agtgtact  12180 tacacatacc aagatggcat agctactaca gacgtaggct ctgtggtaca gg #ccattgct  12240 ccaaggctgc acatctctac aggatggtac tgtactgaat actgtaggca at #tggagcac  12300 agtggtaagt atttgtgtat ttaaacatag aaaaggtata gtaaaaacag gg #tgttacag  12360 tcttaagggc ccaccattgt atttccagtc tccgttgact gaaacatcat ta #tacagtac  12420 atgagcacgt atctttctca cctggtacta gtggaaagct agaaggctta ga #agtctacc  12480 tgtaaacata gcttaagtaa taatacagcc ttatttttaa atgataatag ca #ataatagt  12540 gttcacttat tgagcatttt actatgagtt acttactaaa tatatttcat cg #ttaattta  12600 ctctttgtgt tatttgatct ataacatcgt ttaacaggga aattacctag ta #cataatgt  12660 actgttatct acattttatc tagatgagga aactgaggca cagagaaatt aa #gtactttg  12720 cctaggatta cccgtgaagt taagtgacag aatcaatgaa tctggaaggt ct #ggcttcag  12780 atctcttgtg ctgagtcact cgcatacttt actacctcta aggtttctaa tc #agaggaat  12840 ttgtatctgt attccctgct actcttaccc tctatgtggg atttggcctt tc #tccattat  12900 ccctgtgaac tcgctctggg accttccttc ttgtacttgg aaccatcaga aa #gtgatctg  12960 agaacataga aatctactgt gttgtgaaac agaattacct ggaagcggaa aa #agccctcc  13020 tggctcaatt cacatgtcac ggcttatggt cgtatccggg gaacatatga aa #ctgggcac  13080 tgagtgcgga gtcaggaaag ccctgtccat cctctgggtt tctggggaaa ac #gtggaccc  13140 cttcattgtc actttctcct gtatattttt gtttttactt ttagaactgt ac #aattacgt  13200 aataaataat aaaaagtcgt tggaaggata ggtgaagttc agaagtgaaa gt #gttttgga  13260 ggagtctaag ctccttccca ccctcattga cctttcctct ctaataaata ga #actggtct  13320 aaccaaggat ctgtggaatg agcagagtcc aacggagatt cagggattct aa #taacctct  13380 tgtagaatca ctggtttgtt tcagccacaa gaaggaatta ccttttgaca tt #ggcttgaa  13440 cagctgttgt gcaaagaaaa actttttgga aagttctgga agtaccagat tg #attttata  13500 ggtttttttt tttttttttg gagggacatg ggggtattga cagttgatgt ta #atcagaaa  13560 tcctaaatta tgtgtattcc tggtatgttg caatcagccg gccacctggt tt #tcctctgg  13620 gctcttaatt ttaggtgtat tccgaggaag tttttctaac ttttctgtaa ac #acagacca  13680 ggtatattgc atactttcaa tgtttaacca aatctcttca ctgtttgcag ta #ttatctgt  13740 aggctctcat gttttaagac ttccccatgg tgtttttgta ttgtattttg ct #aacctata  13800 aacaattctt tgaacttaaa acaagatatt tgggcagtaa caataaattt ta #aaaacatc  13860 aattcaactt ttttacatta gggcttggac tatggaaaaa gtattgggca gc #atgcctca  13920 tactgagttg tttaatgaat ttaaaagtat agccnnnnnn nnnnnnnnnn nn #nnnnnnnn  13980 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14040 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14100 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14160 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14220 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14280 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14340 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14400 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14460 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14520 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14580 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14640 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14700 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14760 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14820 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14880 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  14940 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15000 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15060 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15360 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15420 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15480 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15540 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15600 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15660 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15720 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15780 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15840 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15900 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  15960 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16020 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16080 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16140 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16200 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16260 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16320 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16380 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16440 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16500 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16560 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16620 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16680 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16740 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16800 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16860 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16920 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  16980 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17040 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17100 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17160 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17220 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17280 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17340 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17400 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17460 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  17520 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnggt ggagagttct gt #agatgtct  17580 gttaggtctg cttggtccag agctgagttc aagtcctgga tatccttgtt aa #ccttttgt  17640 cttgttgatc tatctaatat tgacagtggg atgttagact cgcacacaat aa #taatgaga  17700 gactttaagt ctttttctag gtctctaagg acttgcttta tgaatctggg tg #ctcctgta  17760 ttgggtacat atatgtttaa gatagttagc tcttcttgtt gaattgatcc ct #ttaccatt  17820 atgtagtggc cttctttgtc tcttttgatc ttagttggtt taaagtctgt tt #tattagag  17880 actaggattg cattccctgc tttttttttt cgcttggtag atcttcctcc ag #ctgtttat  17940 tttgagccta tgtgcatctc tgcacgtgag acgggtctcc tgaatacagc ac #agtgacgg  18000 gccttgactg tttatccaat ttgccagtct gcgtctttta actggggcat tt #agcccact  18060 tatatttaag gttaatattg ttatgtttga atttgatctg tcattatgat gt #ttgctggt  18120 tattttgccc attaattgat gcagtttctt cctagcctcg atggtcttta ca #atttggca  18180 tgtttttgca gtggctggta ccagttgttc ctttccattt ttactgcttc ct #tcaggagc  18240 tcttttaggg caggcctggt ggtgacaaaa tctctgagca tttgcttgtc tg #tgaaggat  18300 tttatttctc cttcacttgt gaaacttagt ttggctggtt atgagattct gg #gttgaaaa  18360 ttctttaaga atgctgaata ttggccccca ctctcttctg gcttgtaggg tt #tctgctga  18420 gagatctgct gttagtctga tgggcttccc tttgtgggta acccgacctt tc #tctctggc  18480 agcccttaac attttttcct tcatttcaac gttggtgaat ctgacaatta cg #tatcttgg  18540 gattgcgctt ctcgaggaat gtctttgtgg tgttctctgt atttcctgaa tt #tgaatgtt  18600 gacctgcctt gctaggttgg ggaagttctc ctggataata tactgaagag tg #ttttgtaa  18660 cttggttcca ttctgtctat cactttcagg tacaacaatc atagcattgg tc #ttttcaca  18720 tagtcgcata tttattgaag cctttgttca tttcttttca ttcttttttc tc #taatcttg  18780 tcttcttgct ttatttcatt aatttgatct tcgatcactg atatcctttc tt #ctgcttga  18840 tcgaatcggc tattgaagct tgtttatgct ttgtgaaatt cttgtacttt gg #ttttcagc  18900 tccatcaggt catttaagct cttctctaca ctggttattc tagttagcca tt #tgtccaac  18960 cttttctcaa ggttttaagt ttccttgcga tgggtcagaa cgtgctgctt ta #gcttggag  19020 aagtttgtta ttaccaacct tctgaagcct acttctgtca actcgttaaa ct #cattgtcc  19080 atccagtttt gttcctttgc tggtgaggag ttacgttcct ttggaggaga ag #aggcgttc  19140 tgtttttgga attttcagcc tttctgctgt ggtttctccc catctttgtg gt #tttatcta  19200 cctttggtct ttgattttgg tgacgtacag atgggttttg gtgtgggtgt cc #tttttgtt  19260 gatattgatc ctattccttt gtttgttagt tttccttcta acagaggccc gt #cagctgca  19320 ggtctgttgg agttgctgga ggtccactct agaccctgtt tacctgggta tc #accagtgg  19380 aggctgcaga acagcaaata tcgcggcctg atccttcctc tggaagcttc gt #ccaagaag  19440 gacacccacc tatatgaggt gtctgtcggc ccctactggg aggtgtctcc tc #ccagtcag  19500 gctacatggg gctcagggac ccacttgagg aggcagtctg tccgttactg ga #gttcaaat  19560 gccgagctgg gagaaccact gctctcttca gagctgtcag gcagggatgt tt #aaatctgc  19620 agaagccgtc tgctgccttt tgtttagata tgccctgccc ccagagatgc aa #tctagaga  19680 ggcagtaggc cttgcggtgg gctccaccca gttcaagctt ccttgctgct tt #gtttacac  19740 tgtgagcata gaagtgcgta ctgaagcctc agcaatggcg gggaggcgct tc #ccctcacc  19800 aagctccagc atcccagctt gatctcagac tgcttggcta gcagcaagca ag #gttccatg  19860 ggcatgggac cccccgagcc aggcactgga ggcaatcacc tgctctgcca gt #tgcgaaga  19920 ctgggaaaag cacagtattt gggcagagta tactgttcct ccaggtacag tc #actcacgc  19980 ctttccttgg ctaggaaagg gaaatcccct gaccccttgc acttcctgga tg #aggtgacg  20040 tcctgccctg ctttggctca ccctccatgg gctgcaccca ctgtccaacc ag #tgccaatg  20100 agatgaacca ggtacctcag ttggaaatgc agaaatcacc catcttctgc at #cgatcttg  20160 ctgggagctg tagaccagag ctgttcctac tggggcatct tggaagcaac tc #tgggtctg  20220 agtttctgtt tgttgccctg atgtatatcc ccagtgccta gaatgatact tg #ttacatag  20280 gaagtgcttg atccatgttt gcacaaatga atctttctca taatgaggtt tc #tctaaaca  20340 agctgttctc ccaaaaactt acacccagct ttatgttgaa gcatctcatt at #acattgga  20400 aagatgaaat gtgtagtgag actttgaatc ttcttttgaa tctagaaaca tt #agcatttt  20460 tagaccattc tattttaata tttatgaaat ttatgaaata ataagaaaca tg #aggccggg  20520 ctcagtggct tatgcctgta atcccagcag tttgggaggc cagggctagt gg #atcatgag  20580 gtcaggaatt tgagaccagc ttggccaaca tggtgaaacc ccacttctac ta #aaaatata  20640 aaaattagct gggcgtggtg gtgcatgcct gtaatgccag ctcctggaga gg #ctgaggca  20700 ggagaatcat ttgaacctgg gaggcggagt ttgcagtgag ctgagatcgt gc #cattgcac  20760 tccagcctgg gcaacattgc gagactccat ctcaaaaaca aaaacaaaaa ca #aaaaaaat  20820 gtgtgaccta aattaggctt atagatgaac cattgcagtc atgattaatt cc #gccattgt  20880 ttgccttgtg atctttggtg ccatgtctgt acatatttca tgatttctgt gt #ttttacgg  20940 tttccatttc agatctccct tgagtttaga aatctggctg agaaatacca aa #cagtgatt  21000 gccgacattt gccggagaat gggcattggg atggcagagt ttttggataa gc #atgtgacc  21060 tctgaacagg agtgggacaa ggttagtctc ataaaacagt gtctgtgtgt ga #tgtattag  21120 acagagctgg cagtcctcat agtgaagctc agaacaagaa aagttgtcca gt #attttcag  21180 cccctctggt tttacaattc atctgtttag gttgaatgtc tcatcataaa ca #gtttattc  21240 cagagttaat tccaaaccag cagctatgta ggatatcagc caggctagga gt #agggtact  21300 ggagagaagt gcttatctag acaaagggat gtaattgacc atgaagatta aa #actacaca  21360 tcaaaacata aggtagggtt aggagtcttg cctatttttc ataggaatgg tg #tttgtgag  21420 acttactcat cacttctgtg gaagtaaaga cattttattt atttatttta aa #gccagtca  21480 gatttagcag gcagagacat ttcagacatc taaagtgttg atgtatttca ta #cctttaac  21540 tgtgcttaaa ttaggatctc cgaaaagatg ctgctacatg gtcactacgt ta #gtgtaggt  21600 ccaaggtctt gggcctctta atttttcaaa cctcaaaact tgacagcagt ta #tctttgga  21660 actgctgatt tgtgcttcct aagttaacag catacaatga ctgctagaaa tc #aatttctg  21720 catttaaggt gaagttagcc gggtactatg gtttacctgt aatctcagca ct #ttgggagg  21780 ctgaggtggg aggatcattt gagcccagga gttagacaca agcctaagca ac #atagcgag  21840 accccgtctt tcaaaaaatt aaaaaatgag cagggaattg gtggcatgtg cc #tgtggtcc  21900 ccagctactc tggaggctga ggtgtgggag gattgcttga gcccaagagt tg #aaggttgc  21960 agtgagccat gattgtgcca ctgcactcca acgtgggtga cagagcaaga ca #cctactga  22020 aagaaaataa agttgaagtt aaaacttctg gccaagaacc agcactggtt at #gatagtaa  22080 ctcattttct gttgtgcaga tttattcagg aaacttaatt ttaggttgtt ga #atagaagt  22140 tttgatcaga taaaattgaa ttaaaaaaaa ttttttttga gacagggtct tg #ctgttatc  22200 caggctggtg tgtagtggtg tgatcacggc tccccgcagc ctcaacctcc tg #ggctcagg  22260 tgatcctccc acctcagcct accgagtagc tgtaactaca gtgcatgaca cc #ataccagg  22320 ctcatttttg tacatttttt gtagagagag ggttttgcca tgttgcccag gc #tagtctca  22380 aactcctggc atcaaacagt cctcccactc tggcctctca aatgttggga tt #acaggcat  22440 gaccagccaa ttatttcaag gagttatttt ttttcttcta ctttggggga ag #atgaatta  22500 tataagtctc cattttagga gtatttctac caaaagaact attatcttca aa #tatatttt  22560 tggatagtac tatagatata ctaatttttt tttaaatttc tagtaattct tt #tgaagatt  22620 ttgtatagct gtccaaagcc aatttctgtc tacctaattt cagcaagatt tc #actctttt  22680 catgttactt ttgtcccaga acaaatttca agtgctttct cttcacctgt gc #attcttcc  22740 ccctgattag tctctggctt tgtattactt tcagtcagag acgacttttt tt #ttttgaga  22800 cagggtctca ctctgtcacc cagactggaa tgcagtggca cagacaaggc ag #ccttgacc  22860 ttctgggctc aagcaatctt ccttgccctc agcctcctga gtaactggga cc #acaggcac  22920 gttgccacca tgcctggcta atttatttta atttttatta tttttgagac ag #ggtattgc  22980 tctgtcaccc aggctggagt gtagtggcat gatcaaggct cactgcagcc tt #cacctcct  23040 gtgctcaagc agtcctctca cctcagcctc cccattagct gggactatag gt #ccacacca  23100 ctacaccagg ctaatttttg taattttttg gtagagacag ggtttcatcg tg #ttgcctag  23160 gctggtcttg agctcctggg ctcaagcgat tcacctgcct tagcctccca gg #tgtgagcc  23220 actacactca gccttttaaa attttttaca gagatgaggt cttgctttgt tg #gccaggct  23280 ggtctaaaac tcttgggctc aagcagtccc ctctccacag cctcccaaaa tt #ccgggatt  23340 acaggcgtga acttcggtca tttcctaact tttacccttc ctaatgacac tc #cagagctt  23400 accttcttta cttttgcttc ttaagttaac taatagacaa ttattgtatg tg #gatattgc  23460 attaagttgt cttaggatac ccttttcaga ggaggacagc ttttgacaaa tt #gctgtcgc  23520 ggaaaaaaaa agtatttggc aattaagagt tgcatttact gaaatctctg tt #gagagagg  23580 ggaagttacg ttgtctctaa aagaaaaact aaaaagaaaa ggggaagttt ta #gcaaagtt  23640 gttaaagcct gacacttaag tcatactacc tagttttgaa ctcttagccc ct #gccacaga  23700 cacggcagcc ccttgaacct tcctgggttc aagcgagcct cctacttcag cc #ccctgagt  23760 aactgggacc actggcctgt gtcactgtgc ctggctaatt tttttttttt cc #tcacatgg  23820 gcaatgttgg gcaagttaaa tcgacttctt tgtgcctcag tttcctcatc tg #aaatggag  23880 atcatactgc tatgtacctg atacaatgtt tgtgaggatt gaatgtgcag ag #ttcttttt  23940 ttctgttgtt gttgttttga gacggagtct cactctgnnn nnnnnnnnnn nn #nnnnnnnn  24000 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  24060 nnnnnnnnnn nnnnnnnnnn nnnnnnnnna tctcgtgatc cgcccgtctc ag #cttcccaa  24120 agtgctggga ttacaggcat gagccatcgt gcccggctga atgtgcagag tt #cttaaaac  24180 cgtgtcaaga acataaaata gttatttgtt ctttcatata atgatgattt tg #agggcctg  24240 cggatcttga catgttatca gattggtcaa aaaaagatta aaccatagtt gg #tattgtcc  24300 tagttcctgt taccagaata ttccatcttt catcgttgcc ttctctcata gt #tttatgta  24360 tcaaaaagtt tattgtaaag ctaggccggg cacggtgtct tgggctggta at #cccagcac  24420 tttgggaggc caaggctggc agatcagttg aggtcaggag ttcgagacca gc #gtggccaa  24480 catggtgaaa ccccgtctct actaaaaata aaaaattagc tggatgtggt gg #tgggtgct  24540 ttaattccag ctactcagga agctgaggca ggagaatcac ttgaacccaa ga #ggcagagg  24600 ttgcagtgag ttgagattgt gccactgcac tccagcccag gggacaaagt ga #gacttgat  24660 ctcaaaaaaa aaaaaaaaaa aaagttattg taaagctaga cacggtggta tt #tgcctaca  24720 atcccagctg ttcgggaagc tgaggcagaa agattgcttg ggtccagtag tt #tgagtcta  24780 acgtgggcaa atatatgaga ctccatctca aaaaaaaaaa taaaaaataa aa #ataaaaaa  24840 atgtttacta gtttttttca gtagcctttt attatagtag cagtacatgt gt #attgtaga  24900 aatttggaaa atacaagtga aaaataaaaa catcaaattc ccgtcagcca ga #gactgctg  24960 tgaaatgttt tgagcacatc cttcttgaat gttttttaaa tcctggtatg ta #tatttgta  25020 ttttaaaatc aaaatgcatt cttacccatt ctcttttgaa cctgcttttt tg #tagctaat  25080 gatctctagt gtgtccattt cagtaaaaat tccattatta aagtgcttta aa #aatcgtct  25140 cttacagtac tgccactatg ttgctgggct ggtcggaatt ggcctttccc gt #cttttctc  25200 agcctcagag tttgaagacc ccttagttgg tgaagataca gaacgtgcca ac #tctatggg  25260 cctgtttctg cagaaaacaa acatcatccg tgactatctg gaagaccagc aa #ggaggaag  25320 agagttctgg cctcaagagg taacagattc agggtatttt gggggaaaat aa #ctttagac  25380 attctctgaa aaatccttta actcttgtgg ttgcgggtga cagaaaaaca ag #ccaggcct  25440 cccccaggca gcataagggg atgtggaaaa taggatagat tgacatgagt tt #gcttcagg  25500 tagactggct gactcccagg attcacacca cgtaatcagt atattcaagc ct #tgctgtcc  25560 ttgatttctt tcagacggtc tttctccaag tggtggatat ggtaacaacc ca #cgtgcact  25620 agcttaacaa aaagttctta ggaatggctt tgttcggcct ggcgcagtgg ct #catgcctg  25680 taatcccaac agtttgagag gccaaggtgg gcggatcacc tgaggccagg ag #ttcgagac  25740 cagcctggcc aacatagtga aaccccgtgt ttactaaaaa atacaaaaat ta #gccgggcg  25800 tggtggcaag ggcttgtaat cccagctacc tgggaggctg aggcaggaga at #cgcttgaa  25860 cccaggaagc agagattgcg gtgagctcag attgtgccac tgcactccag cc #tgggcgac  25920 agagtgagac tccctctcaa aagaagagga agggcttggt tcttctgctc ag #ccctgaat  25980 cagttactgt tgctacacag ctgagttctc tggcctcacc tggattacgt ct #acacagta  26040 cacacagaat ggatttcccc caaagaaaga attctgcggc aggaagggga aa #gggatggc  26100 aggtagacaa aaactccagg tgtctgtaat aagggacagg gtcgatcttt aa #ttaaaaca  26160 tggacaggga acagaaagct tttgatactg attttgttca gaaggaaagt ag #aaaatttt  26220 atgactgttc cctgaattta ttccagcatt taccttttgc tttccataaa ag #tgtttcct  26280 gcagccaagt actttaaagt tttaaaaaga cgggtgaggc taagtgtggt gt #ctcatact  26340 tataatccca gtgctgaggc caggagttca agaccagcct gagcaacaca gc #aagatacc  26400 atctctataa aaaattgtta gaaaatgatt ctgctgaaag agcaaaaata aa #aattaaag  26460 aaagtagaaa aaataaaact aaatttaaaa gattaactgg gcatgttggc at #gcacctgt  26520 attcctaggt attcgggagg ctaaggcaca aggatccctt gagcgcagga gc #tcaaggtt  26580 ggattgagtt gtaatcacac cactgcactc cagcctcggt ggcacaatga aa #ctgtctca  26640 agaaaaaaaa aaagtgacag agggaaacaa tatttgcaat tcatagagca ga #tacagggt  26700 tcatattcct aatattaaaa aaaacttcta aaagttaaga aaaaggccaa ct #gccccaca  26760 gaaaaatggg caaggagata agaacaagat tgttcacagg aagagacaca ca #gatgatta  26820 ttaaaaatct gaaaagatgc tgagtcttac tcctaagaaa aattcacatt ta #aactactc  26880 tgggggctgg gcaaggtggc tcacgcctgt aatctcaaca ctgggagacc aa #ggcaggaa  26940 gatcactgaa gccagggtat cgagaccagc ctggacaacg tagtgagacc tt #atctctta  27000 aaacaaaaca aaacaaaaca aaacaaaaaa aacagtaaaa attggccggg ca #cagtgact  27060 cctgcctata atcccagcac tttgggaagc ccaggtgagt ggatcacttg ag #gtcaggtg  27120 tttgagaaca gcctggccaa catggcaaaa ttccgtctct actaaaatta ca #aaaattag  27180 ccaagtgtgg tggcatacgc tggtagggcc agctacttgg gaggctgatg tg #agactcca  27240 tttaaaaaaa aaaaatcaaa aattagctgg gtatagtggc acacccctat ag #ttctcgct  27300 ccttgggagg ttgaggcagg aggattgcct gagcccagga gttcaaggct gc #agtgaacc  27360 atgatcacac cactgcattc tagcagcctg ggagacagag caaaaccctt gt #ctcaaaac  27420 aaacaaacaa caacaaaaac aaaaaacact tccctcagct cagacatggc ct #tttaagtt  27480 tcctaggtga ctcgtgtgca gccagggttg agaaaccact cttgtcttac cc #ctcttttg  27540 cagacacagg gctcagagaa gggaagggga ttgtctgggg atgtatagtg ag #gcagtggc  27600 tgccttggaa gtggagtctc agtctcccgg ctcctaggcc agcccctgac ca #ctgttcca  27660 ttgtctccca gacagaacat cagccacggg catgtgatgc atgagcgtga gc #cacaccat  27720 cttgcacaca caggagcaga gccctgctct tctcattcac ttactttatc tg #taaaatag  27780 catcatttct accacacggt ggtggtgtga ataaaatgag atgaacttct ag #catagagt  27840 gcttagtaaa ggttctggac atttcgtagt agttgaatca tgccaaatgt gg #tcctaggt  27900 gattggcttc ttttgctagc atgttttcag ggctcctcca tgctggggca tt #gcatcact  27960 gctttattcc tttttatcgc ctagtattat tccactgtgt ggatagacca ca #tttatcca  28020 ttcatcagtt ggaggatatt tgggttcttc ccattttttt tggctatggt ga #atagtact  28080 gtgtacattt gcatataagg ttttgtgtag atgtgtgttt tcctttttct tg #ggtctatg  28140 ctgagaagtg gaattgctgg ttcatacagc agctcgaacc ttgtgaggag ct #gccagacg  28200 cttttccaag gtcgctccac cattttacat tcccgtcagc agtgtgagag tc #ccagtttc  28260 accagcactt gttgttatct ctttttaact gtatgtatat atacttaaca tt #ttatttat  28320 aataaatgta cataatagag aatttgccat tttaactatt tttaagtcta tt #attcagtg  28380 gcattaagta cattaatgat gttatataac catcaacact atgtttccag aa #ctttcgct  28440 agcttcagag aatcctctaa ataatatcat taaaaatcat caagccgaat cc #cactgtta  28500 gaattaaagg ttttatttca ctttcaagtt atcaggatcc agggaggtgt aa #tacactta  28560 gaggatagac tcagctcatt tcccagctat gcctttcagc agcattctta cc #agagtagg  28620 aatataatgt tagtcattat ttagaggcct ggccatcttg agaaggttta ct #gtttagtc  28680 tgcagtacaa ttataactgt ttttgtatat tgggttattt ttttcagaag ta #ggccagta  28740 gctctaacag gagcctcttt agcctgaatt cgtccaagta gtgcagtgtt gc #actagttg  28800 tccctcggga catgctcccc aatacgtaac tcacttccag gttgcaactg ga #cacttact  28860 ggtagtcaga aatagctatt gcatggagct taaaatgaac ttgatcttcg tg #aaagatga  28920 gtctgcagct aagagacttt actgtatatc atagtgtttt tttttgtttt gt #tttgtttt  28980 tgtttttgtg acggagtctc actctttcac ccaggctgga gtgcaatggc ga #gatcttga  29040 ctcactgcaa cctccgcccc ctaggttcaa gcaattcttc tgtctcaccc tc #ctgagtag  29100 ctgggattac aggcgcctgc caccgtaccc ggctagtttt tgtattttta gt #agacacag  29160 ggtttcacca ccttggccag gctggtcttg aactcctgac ctcgtgatcc ac #cctcctcg  29220 gcctcccaaa gtgctgggat tacaggcgtg agccacggcg cccagcctgt at #catagttc  29280 ttatgcacaa agacccttta atattgtttg taaattctcc cctatgcaca cg #ctgacctg  29340 ttccttaatc ttcttatctg tctaggtttg gagcaggtat gttaagaagt ta #ggggattt  29400 tgctaagccg gagaatattg acttggccgt gcagtgcctg aatgaactta ta #accaatgc  29460 actgcaccac atcccagatg tcatcaccta cctttcgaga ctcagaaacc ag #agtgtgtt  29520 taacttctgt gctattccac aggtagggaa cggggctcct ctgggtggat ac #ggggctaa  29580 agggagtggg gtaggagtaa gggtggattt tgctgtgcta tattcaagga ta #tgattcct  29640 taaaaagacg atgactccag tttattacgc tgggagtttc atagcacccg cc #tttgcttc  29700 cagccaccaa actcagctca gccttgaggt taagcctgct ccttttcaga ac #cttctttc  29760 cggatttact attttctaca gctatcctaa actagttagg ttcttttcct ca #cagttaag  29820 tcaaggtctt tggcttagat ttatggggag tgctgggtaa aacctgggtg aa #gctgttat  29880 cattaaaaag tcttcattaa gcacctaatt actgctgtcc ttttcctaga cc #cggcataa  29940 aaagaacctg gtccggtaga cctagcctct cagtatgcta ggaacttaca ct #ttttagtt  30000 gcctttacca agtattgcag atactactgc aaataagtga agaaagtaac ag #catttaac  30060 tgatttggga acttggtttg atcttgttct aatgacccac ttcgaatggt gg #ttgaaagt  30120 aaaatctgta tcgccgtctt atgtttccat ttacctagaa atactttacc tt #tgagcaca  30180 ggaaattaat ccccttctgg ttgttctccc cctggcattg gttttaaata ta #taatgatt  30240 atgtttgttg taggaaaaat agaaaaacaa ctacaataga aaattcttcc ca #tatattat  30300 tttgaaatac atatttccga tccgataatc cattgctcta gcatggaaaa tg #ttggattt  30360 acttgtgttt gctttttcca aataaaatgg aacttttgtg gctacattat ag #aattgttt  30420 tagactgctt aattctgtgt gttgttgaga aagggaggag tggggaaggt aa #aaatcttg  30480 acatactttc ttcgtgggta ttttttcttg agcgattcca tcttagttga tt #agcagtta  30540 gcaattgccc attcaacaga aggttttctt acctttttgt gataatgata gc #taacgaca  30600 tcatttcttc ttttttccct ctcttcttgt tgtctctagg tgatggccat tg #ccactttg  30660 gctgcctgtt ataataacca gcaggtgttc aaaggggcag tgaagattcg ga #aagggcaa  30720 gcagtgaccc tgatgatgga tgccaccaat atgccagctg tcaaagccat ca #tatatcag  30780 tatatggaag aggtgggttt ttatttaact acttggataa tttgtagcta ct #tttatgat  30840 ttagtaatgt cactgtttaa ccaggtttgg atattagatg atcctaacaa tt #cactatcc  30900 tgtggcctaa agagacagga attgatatcc tttataagga aaaaagtcta tt #cacaggag  30960 ccgagcagat tgctcactgc tgtgtagtac cctggtgaga ggagataaat gg #agcaaggc  31020 tgtaggttgg agcccctcag tagaatcata gattttgagc tgcaagatga tg #caggaggc  31080 caaccaagct tcttgttgct ggtgaggaat gtgaggttga agcttgtctg tg #ctgatgca  31140 gtgcgtgatt gagtggatct ctggctcccg tccatgtgtc ctgacaccca gt #ctggtact  31200 ttcattatgc cacaggcctc aattgaaaaa tcacagtagg gaatttaggc ca #aggaaagc  31260 catcaagttg caattatttc ctaaattttc tttggaaaat ttcatttcaa at #accaaaac  31320 catcctataa aaagaaaact taccttctta ggtcaaatct ctaatatttg ac #taggttca  31380 aaaagtttat ttctggccag gcacagtagc ttactcctga aatcccagca ct #ttgggaga  31440 ccaaggtggg aggatcactt gaggccagga attcaagacc agcccgggcg ac #atagcaag  31500 accccatttc tacaaaaaat ttaaaaattg tcatggtggt gcacgcctgt gg #tcccagct  31560 actcaggagg ctgaggcagg tggatcacat gagcctgaga ggtcgaggct ac #agtaagct  31620 gtgtgatttc atcattgcac tctagcctgg gtgatagagt gagactttgt ct #caaaaaaa  31680 aaaaaaaaaa aaaaagtctt agagaccaga agtctctgta atctctaata at #ctctaggc  31740 cctagagcag tggtttgtaa atggaggtga tttgctcccc tccccccaga gg #acattgga  31800 caatgtctgg agacattttt gattgtccta accggcagga atcgggtgct ac #tggcatct  31860 ggtgagtaga ggcccaggat gatgctgtga tcctcaggtg tgatcctgtt ga #gaatgaaa  31920 cactgtagac tttatgaaaa catacaagac cctcatcatt tttcctttgc ct #gagctccc  31980 tccccagagg ttacctctgt tcatggtttt gtgcatccgt ctagtccccc tg #ttacgcgt  32040 ttacaggaat atggtttgca acagtgtttt catctaaata gaattataca aa #atagcgat  32100 ttctgatttc tcttgcatat tgcacattct tcttatactt cctccctacc tt #tatctgac  32160 acagaaatgc tgtatgtcca gaacttctat cagaggcacc tatggaagtc ta #agggaaga  32220 ccacatcgct tttaaaaacc ctaaaatttt gtagtcacta gatgaaaata tt #cagccagt  32280 gacccaaaaa attgctacca atgagactct ccattttgcc atgtagccag aa #cttacttt  32340 gatctatgtg cctggggtag tgaccaagta ggtgggtagg agtaatctca gg #gaaacttg  32400 aggccccagc ctcatggcta gggtcataat ttgaacccag gtctgtctga ca #tcagaatc  32460 catgatgtta accccaattc taaggggttc aactaccctt tctaaatgga at #cctgctat  32520 attaagcact atttattcat tttatataaa ctagaaacat tttatgtagt aa #gtagttga  32580 gagtgttttg gttttgcagt ttgatcacta gttttagaaa ccagttttta aa #cactttgt  32640 ggccaattcc attactatat taaaattcag atttatttgg tttttcctta ac #tattggga  32700 ttaaatcctg gttgtaattc atagtttgag ggcgagggtg ggcagtctac at #ttggctga  32760 gccctgtttt tgtgaataaa tgttatcaga acacagccac acccatttgc tt #ctatgtct  32820 tctgtggctg cttttgcaat gtgacggccg agttgaggag ctgcaacagg cg #atgacttg  32880 taaagctgaa aatatttttt ggcccttgaa taagaggttg gctgacttct ga #cttagggc  32940 atcagttgtt ctgttatccc agtaaaactc aaggcattag gggagaaatg tt #aatattaa  33000 tacttaagtt gatttgattt agggaaatct ttgaagattt ctaagtctta ag #cagtagaa  33060 cctgttaatg gttttagttt cagcagtaag gacattttac aagtaaagtt tt #aaatgaaa  33120 acattttgta tgaagccaca agtcgtctgg cctcttgctg gtgtccagat at #taacactg  33180 atcctatttc tccttgctga ccaagtctgt cctttgtagt aagaaaggaa ga #aacgttga  33240 ctctgtccga tctctggact tagtgttgta gcgagcatgc acctggaagg ga #cttgccag  33300 aggacctcct catgcttctc cagtgcttag tgggggcttg gagtgcagcc cc #aggtcttc  33360 acgagcagtt ggccacactg cagggccctc accccactct ggagcagcct ct #gcttcaaa  33420 ccagcctgga tgcttgtcag ctggggagaa gatcaacctg ctattttggg at #agaaataa  33480 atgctcagcc aaacggccag aaacccccat tcccctctct gccaaagtga at #tccttggc  33540 agggagaagc ttgttcgtgt ctctgcacac ttcctgtgcc ctcctgtggt ta #agtcagag  33600 aatcatccgg ctctttgagc cccaggtgcc tagctgctca aggatggtcc cc #agccagca  33660 gctgccagga atcacctggg agcccattaa gacatccagc ccccacccaa ac #ctatcgaa  33720 tcagaatctg cctttttttc ccaaatgatg tttttgcttt aatggaagtt ta #gatgttca  33780 tagacaagag ttttaaatga tgatcaagct gattccatat tcgcagttgt aa #gtagaact  33840 gctgagacgt ggaagtacca catggactca cagaggagct gctgtatgta gc #acagcatt  33900 gcacaagagc ttatttcagt ctagtaaaca tttataggag cctgtgtcat tt #aatcatca  33960 agcctcgcac tgtggctcac acctgtaatc ccaaaacttt gggaggctga gg #caggcaga  34020 tcacttgagg taaggagttc gagaccagcc tggccaatat ggcaaaaccc tg #tctctact  34080 aaaaatacaa catttagcca ggtgtggtgg tgcacacttg tcatcccagc ta #ttccggag  34140 cctgagacat gagcatcgct tgaactcggg aggtggaggt tgtagtgagc tg #agatggca  34200 ccactgcact ccagcctggg caacagggtg aaggcccttt ctcaaactcc tc #aagtattt  34260 ggcttcaact ttatgccggg catgtagatg aaaagtcggc tatgacctgt cc #ttgacaag  34320 cagatgtaac tccttgattg aggctagtag gtttttaaga cctgaataat tg #agtttgca  34380 gaaacctact gtgtgccttc aggtaaatgg agagtggggt ttggtctagc aa #cgaagcat  34440 ctagaaggtc tctttggcct taccggctct gttttaggta agtccacgtc tg #agtaccag  34500 tgactgcagc tcttccagtt gtgctgtcat gtttatatgt tagaaatgat ca #tcaaagga  34560 ctcaaaagtt ttgccactaa ttgtattacc ggggactgtc acaaccaaga tt #tctcttaa  34620 tttattcacc ttacttatct cctggaaggg catattgaag tgctcttgga gt #tctctaaa  34680 agggtttttg ttggttgtgt atattcactt gggtgccagc gattgattcc aa #ataagtaa  34740 atcttttttc ccaaaaggat gtaagatggc ttatggttat aagtacaaca gg #ctaacaaa  34800 gtacaagtag atgagaaagt aaaatgaaga aataaagtca taggagccac ag #aattaacc  34860 caggaatgaa taagtgtgta gtttggtgct gatgttatca tcctttattt gt #acattgct  34920 tgtacagttg ctctgagaag gtaagtctta aattttcaaa agtgaaatgt ca #ccgagcat  34980 ggtggctgat gcctctaatc tcagcacttt gggaggctga ggcaggcgga tc #acttgagg  35040 tcaggagttc gaaaccagcc tgacttatgt gatgaaaccc tgtctctact aa #aaaaaaaa  35100 aaaaaaaaaa aaaaaaaaaa aaaaatccaa aagttagttg ggcatggtgg ca #ggtgcctg  35160 taatcccagc tacttgggag gctgaggcag gagaatcgca tgaacctggg aa #gtggaggc  35220 tgcagtgagc caagattgca ccactgcact ctagcctggg tgacagagcg ag #acaccatc  35280 ttaaaaaaaa aaaaaaatct acaatatacc aaaaccatta cttacctgag aa #actattct  35340 cagggtcatt gtagtgaatg cctattttat ggcttttgat ggcatcaggg ca #ctcaggtc  35400 atttacaaga gtagtgtgtg agaccctgtg tgtcactgcc actcatcttg gc #cttcggcc  35460 actgctgtag caaccagttt ccaagtaggg ctggaccttg ccttctgctc ca #gagacctc  35520 tcgcttcctg cccttgggct tctgacgagc tgcaggaact gcctggcacg tg #ggtcccca  35580 caacccagag gaggtgaggg ccacctctct gctcctcagg gccacctttc at #aaggctcc  35640 ttgaaggtcc ctcaagatca agccaactca acacatcctt gataggcctt cc #tgccttct  35700 gtttcacttc tccactcgtt tccaaataaa tggctgcatg caagcttttg cc #tcaggttc  35760 tgcttttagg aggaaggcta agacaagcag taaagcaaca tgggcaggca ga #aggatgac  35820 ttctaataga attatctcat cactatatat tttactttat ggatgcttgt at #tgaaaagt  35880 cttggctggg tggagtggct cacgcctgta atcccagccc tttgggaggc cg #aggtgggt  35940 ggatcacttg aggtctggag tttgagacca gcctgaccaa cactggtaaa ac #cttgtctc  36000 tattaaaaat gcaaaaatta gccagggatg cacgcttgct gtgtgccagc ac #agggctag  36060 gctggagata aaaaggtgag taagtaggtg cggtgtagtc agggtgaaaa ct #acagatgg  36120 tccatttcca cgtaagtgga aaggtaaagg tatgtacaat agggtggctc ct #ggctgaac  36180 ctggagctgc agacaggttt tctagaaggc ataatcctga agttgagact tg #ggggccta  36240 ggtaggagcc agttgaaggg acgtgggagg cgcattccag agagaaggag tg #gtatgaga  36300 ctggaacaga ggtgtgcagc agcatcgcat gggcgaaaca acagtagaca gt #tgttcttt  36360 tgtttttgtt tgttttttga gacagggtct tgttctgtca tccaggctgg ag #tgcagtgg  36420 catgatctcg gatcactgca acctccacct cccaggctca agtgatcttc cc #accccagt  36480 ccccaagtag ctgggggacc acaggtgcat gccacgatgc ccggctaatt tt #tgtacatt  36540 ttgtagaaac agggttttac tgtgttgtcc aggctggtct taaacgcctg ag #cttaagca  36600 gtctacatgc ctcagcctcc tgaagtgctg ggattccaaa catgagccac tg #tgcctggc  36660 ccggcaactg ttactagact atagagaggg aggtgggcaa gggctggtga ca #ctagacag  36720 gtgcagtagg tctggaccat gggtggcctt gcgctacaca ttacagagct ca #ggcttttt  36780 ttctccaggt gagagggctg gtgccactga ggcatcaagc agaggtttga ga #tctccttg  36840 gtgacagtgt agagcagaca ggtagatttg ggaatttaag cttagactca cg #ttggagac  36900 tgagatagct catctgagag gcactcaggg cctaatctca ggcagtaatt tt #agggatgt  36960 aggggaagag atggattctg cacatacttg ggaggcttgt ggaggagtgg gg #agggaggc  37020 acagggagga ctccagggtg gttcatacgg ctccctgctt ctgttcctgt cc #ccctttgt  37080 caagctgtgg tctgtactgc gtgttccatc ttgtttctaa gctgcttttg cc #cagtcttt  37140 ccagcatttc cctttcgtca tgttagtctg tgcctgtcta cgtgaactat gg #tgacgttt  37200 attgggcctg gcactgtgag gtgctgggga tgtgaagatc attgtggctc ag #ccgctgct  37260 ctcgagggcc tctgggtgca gtatgcacac ctgtgcctcc tgtttgctca gg #aagacagg  37320 ctttgagatg agctggggct gacatcccca ccttatcatt gggatggctt tg #ggtaagtt  37380 atgttcatgt tctctgagcc tccctttcct cattggtaaa atgggtataa aa #tacctgcc  37440 agtggagggt tgttgtaagt agccatggaa aatgtaaagc acatagcact ta #ccattttt  37500 tcctgtgtct ttaacagatt tatcatagaa tccccgactc agacccatct tc #tagcaaaa  37560 caaggcagat catctccacc atccggacgc agaatcttcc caactgtcag ct #gatttccc  37620 gaagccacta ctcccccatc tacctgtcgt ttgtcatgct tttggctgcc ct #gagctggc  37680 agtacctgac cactctctcc caggtaacag aagactatgt tcagactgga ga #acactgat  37740 cccaaatttg tccatagctg aagtccacca taaagtggat ttactttttt tc #tttaagga  37800 tggatgttgt gttctcttta tttttttcct actactttaa tccctaaaag aa #cgctgtgt  37860 ggctgggacc tttaggaaag tgaaatgcag gtgagaagaa cctaaacatg aa #aggaaagg  37920 gtgcctcatc ccagcaacct gtccttgtgg gtgatgatca ctgtgctgct tg #tggctcat  37980 ggcagagcat tcagtgccac ggtttaggtg aagtcgctgc atatgtgact gt #catgagat  38040 cctacttagt atgatcctgg ctagaatgat aattaaaagt atttaatttg aa #gcaccatt  38100 tgaatgttcg tactagtaga aaatgatgtg aattttcttt ctgttcggct cc #tatttttc  38160 tcatcatttt gttttcttta attgggttga atggagtaga tagaaatatt ta #tggtttag  38220 gtaacagtta gatgtttcct aagaatgcaa actgcctttt ccacacaaag gc #tgggaata  38280 aaattctggg tattctcgta ttctcattta aaggagttta gctttcagag ag #aaacagca  38340 ggattgcttt tgacctttta gaagattggt ctccagtaaa ggtggacatt tt #tgagattt  38400 ttataataaa gaatttaatt gctctgcatt tgtcaagtac agttcgcttg aa #agcctgcc  38460 tgactgtgga aaagatggag ctcaagaatg gagttgatgg cccagcgtgg tg #gctcatgc  38520 ctgtaatccc agcactttgg gaggctgagg cggtcggatc acgacattag gg #gatcgaga  38580 ccatcctggc taacacggtg aaacccccgt ctctactaaa aaaaaaaaaa at #tagccagg  38640 cgtggtggcg ggtgcctgta gttccagcta ctcgggaggc tgaggcagga ga #atggctta  38700 aacccgggag gcggagcttg cagtgagctc agatcgcgcc actgcactac ca #gtctgggc  38760 aacagagcga gactccatct caaaaaaagg aaaaaattgt aaaaaaaaaa aa #aaaaaaan  38820 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  38880 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  38940 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39000 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39060 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39360 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39420 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39480 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39540 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39600 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39660 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39720 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39780 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39840 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39900 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  39960 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  40020 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn #nnnnnnnn  40080 nnnnnnnnnn                 #                   #                   #     40090 <210> SEQ ID NO 4 <211> LENGTH: 417 <212> TYPE: PRT <213> ORGANISM: Human <400> SEQUENCE: 4 Met Glu Phe Val Lys Cys Leu Gly His Pro Gl #u Glu Phe Tyr Asn Leu  1               5   #                10   #                15 Val Arg Phe Arg Ile Gly Gly Lys Arg Lys Va #l Met Pro Lys Met Asp             20       #            25       #            30 Gln Asp Ser Leu Ser Ser Ser Leu Lys Thr Cy #s Tyr Lys Tyr Leu Asn         35           #        40           #        45 Gln Thr Ser Arg Ser Phe Ala Ala Val Ile Gl #n Ala Leu Asp Gly Glu     50               #    55               #    60 Met Arg Asn Ala Val Cys Ile Phe Tyr Leu Va #l Leu Arg Ala Leu Asp 65                   #70                   #75                   #80 Thr Leu Glu Asp Asp Met Thr Ile Ser Val Gl #u Lys Lys Val Pro Leu                 85   #                90   #                95 Leu His Asn Phe His Ser Phe Leu Tyr Gln Pr #o Asp Trp Arg Phe Met             100       #           105       #           110 Glu Ser Lys Glu Lys Asp Arg Gln Val Leu Gl #u Asp Phe Pro Thr Ile         115           #       120           #       125 Ser Leu Glu Phe Arg Asn Leu Ala Glu Lys Ty #r Gln Thr Val Ile Ala     130               #   135               #   140 Asp Ile Cys Arg Arg Met Gly Ile Gly Met Al #a Glu Phe Leu Asp Lys 145                 1 #50                 1 #55                 1 #60 His Val Thr Ser Glu Gln Glu Trp Asp Lys Ty #r Cys His Tyr Val Ala                 165   #               170   #               175 Gly Leu Val Gly Ile Gly Leu Ser Arg Leu Ph #e Ser Ala Ser Glu Phe             180       #           185       #           190 Glu Asp Pro Leu Val Gly Glu Asp Thr Glu Ar #g Ala Asn Ser Met Gly         195           #       200           #       205 Leu Phe Leu Gln Lys Thr Asn Ile Ile Arg As #p Tyr Leu Glu Asp Gln     210               #   215               #   220 Gln Gly Gly Arg Glu Phe Trp Pro Gln Glu Va #l Trp Ser Arg Tyr Val 225                 2 #30                 2 #35                 2 #40 Lys Lys Leu Gly Asp Phe Ala Lys Pro Glu As #n Ile Asp Leu Ala Val                 245   #               250   #               255 Gln Cys Leu Asn Glu Leu Ile Thr Asn Ala Le #u His His Ile Pro Asp             260       #           265       #           270 Val Ile Thr Tyr Leu Ser Arg Leu Arg Asn Gl #n Ser Val Phe Asn Phe         275           #       280           #       285 Cys Ala Ile Pro Gln Val Met Ala Ile Ala Th #r Leu Ala Ala Cys Tyr     290               #   295               #   300 Asn Asn Gln Gln Val Phe Lys Gly Ala Val Ly #s Ile Arg Lys Gly Gln 305                 3 #10                 3 #15                 3 #20 Ala Val Thr Leu Met Met Asp Ala Thr Asn Me #t Pro Ala Val Lys Ala                 325   #               330   #               335 Ile Ile Tyr Gln Tyr Met Glu Glu Ile Tyr Hi #s Arg Ile Pro Asp Ser             340       #           345       #           350 Asp Pro Ser Ser Ser Lys Thr Arg Gln Ile Il #e Ser Thr Ile Arg Thr         355           #       360           #       365 Gln Asn Leu Pro Asn Cys Gln Leu Ile Ser Ar #g Ser His Tyr Ser Pro     370               #   375               #   380 Ile Tyr Leu Ser Phe Val Met Leu Leu Ala Al #a Leu Ser Trp Gln Tyr 385                 3 #90                 3 #95                 4 #00 Leu Thr Thr Leu Ser Gln Val Thr Glu Asp Ty #r Val Gln Thr Gly Glu                 405   #               410   #               415 His <210> SEQ ID NO 5 <211> LENGTH: 417 <212> TYPE: PRT <213> ORGANISM: Human <400> SEQUENCE: 5 Met Glu Phe Val Lys Cys Leu Gly His Pro Gl #u Glu Phe Tyr Asn Leu  1               5   #                10   #                15 Val Arg Phe Arg Ile Gly Gly Lys Arg Lys Va #l Met Pro Lys Met Asp             20       #            25       #            30 Gln Asp Ser Leu Ser Ser Ser Leu Lys Thr Cy #s Tyr Lys Tyr Leu Asn         35           #        40           #        45 Gln Thr Ser Arg Ser Phe Ala Ala Val Ile Gl #n Ala Leu Asp Gly Glu     50               #    55               #    60 Met Arg Asn Ala Val Cys Ile Phe Tyr Leu Va #l Leu Arg Ala Leu Asp 65                   #70                   #75                   #80 Thr Leu Glu Asp Asp Met Thr Ile Ser Val Gl #u Lys Lys Val Pro Leu                 85   #                90   #                95 Leu His Asn Phe His Ser Phe Leu Tyr Gln Pr #o Asp Trp Arg Phe Met             100       #           105       #           110 Glu Ser Lys Glu Lys Asp Arg Gln Val Leu Gl #u Asp Phe Pro Thr Ile         115           #       120           #       125 Ser Leu Glu Phe Arg Asn Leu Ala Glu Lys Ty #r Gln Thr Val Ile Ala     130               #   135               #   140 Asp Ile Cys Arg Arg Met Gly Ile Gly Met Al #a Glu Phe Leu Asp Lys 145                 1 #50                 1 #55                 1 #60 His Val Thr Ser Glu Gln Glu Trp Asp Lys Ty #r Cys His Tyr Val Ala                 165   #               170   #               175 Gly Leu Val Gly Ile Gly Leu Ser Arg Leu Ph #e Ser Ala Ser Glu Phe             180       #           185       #           190 Glu Asp Pro Leu Val Gly Glu Asp Thr Glu Ar #g Ala Asn Ser Met Gly         195           #       200           #       205 Leu Phe Leu Gln Lys Thr Asn Ile Ile Arg As #p Tyr Leu Glu Asp Gln     210               #   215               #   220 Gln Gly Gly Arg Glu Phe Trp Pro Gln Glu Va #l Trp Ser Arg Tyr Val 225                 2 #30                 2 #35                 2 #40 Lys Lys Leu Gly Asp Phe Ala Lys Pro Glu As #n Ile Asp Leu Ala Val                 245   #               250   #               255 Gln Cys Leu Asn Glu Leu Ile Thr Asn Ala Le #u His His Ile Pro Asp             260       #           265       #           270 Val Ile Thr Tyr Leu Ser Arg Leu Arg Asn Gl #n Ser Val Phe Asn Phe         275           #       280           #       285 Cys Ala Ile Pro Gln Val Met Ala Ile Ala Th #r Leu Ala Ala Cys Tyr     290               #   295               #   300 Asn Asn Gln Gln Val Phe Lys Gly Ala Val Ly #s Ile Arg Lys Gly Gln 305                 3 #10                 3 #15                 3 #20 Ala Val Thr Leu Met Met Asp Ala Thr Asn Me #t Pro Ala Val Lys Ala                 325   #               330   #               335 Ile Ile Tyr Gln Tyr Met Glu Glu Ile Tyr Hi #s Arg Ile Pro Asp Ser             340       #           345       #           350 Asp Pro Ser Ser Ser Lys Thr Arg Gln Ile Il #e Ser Thr Ile Arg Thr         355           #       360           #       365 Gln Asn Leu Pro Asn Cys Gln Leu Ile Ser Ar #g Ser His Tyr Ser Pro     370               #   375               #   380 Ile Tyr Leu Ser Phe Val Met Leu Leu Ala Al #a Leu Ser Trp Gln Tyr 385                 3 #90                 3 #95                 4 #00 Leu Thr Thr Leu Ser Gln Val Thr Glu Asp Ty #r Val Gln Thr Gly Glu                 405   #               410   #               415 His <210> SEQ ID NO 6 <211> LENGTH: 417 <212> TYPE: PRT <213> ORGANISM: Human <400> SEQUENCE: 6 Met Glu Phe Val Lys Cys Leu Gly His Pro Gl #u Glu Phe Tyr Asn Leu  1               5   #                10   #                15 Val Arg Phe Arg Ile Gly Gly Lys Arg Lys Va #l Met Pro Lys Met Asp             20       #            25       #            30 Gln Asp Ser Leu Ser Ser Ser Leu Lys Thr Cy #s Tyr Lys Tyr Leu Asn         35           #        40           #        45 Gln Thr Ser Arg Ser Phe Ala Ala Val Ile Gl #n Ala Leu Asp Gly Glu     50               #    55               #    60 Met Arg Asn Ala Val Cys Ile Phe Tyr Leu Va #l Leu Arg Ala Leu Asp 65                   #70                   #75                   #80 Thr Leu Glu Asp Asp Met Thr Ile Ser Val Gl #u Lys Lys Val Pro Leu                 85   #                90   #                95 Leu His Asn Phe His Ser Phe Leu Tyr Gln Pr #o Asp Trp Arg Phe Met             100       #           105       #           110 Glu Ser Lys Glu Lys Asp Arg Gln Val Leu Gl #u Asp Phe Pro Thr Ile         115           #       120           #       125 Ser Leu Glu Phe Arg Asn Leu Ala Glu Lys Ty #r Gln Thr Val Ile Ala     130               #   135               #   140 Asp Ile Cys Arg Arg Met Gly Ile Gly Met Al #a Glu Phe Leu Asp Lys 145                 1 #50                 1 #55                 1 #60 His Val Thr Ser Glu Gln Glu Trp Asp Lys Ty #r Cys His Tyr Val Ala                 165   #               170   #               175 Gly Leu Val Gly Ile Gly Leu Ser Arg Leu Ph #e Ser Ala Ser Glu Phe             180       #           185       #           190 Glu Asp Pro Leu Val Gly Glu Asp Thr Glu Ar #g Ala Asn Ser Met Gly         195           #       200           #       205 Leu Phe Leu Gln Lys Thr Asn Ile Ile Arg As #p Tyr Leu Glu Asp Gln     210               #   215               #   220 Gln Gly Gly Arg Glu Phe Trp Pro Gln Glu Va #l Trp Ser Arg Tyr Val 225                 2 #30                 2 #35                 2 #40 Lys Lys Leu Gly Asp Phe Ala Lys Pro Glu As #n Ile Asp Leu Ala Val                 245   #               250   #               255 Gln Cys Leu Asn Glu Leu Ile Thr Asn Ala Le #u His His Ile Pro Asp             260       #           265       #           270 Val Ile Thr Tyr Leu Ser Arg Leu Arg Asn Gl #n Ser Val Phe Asn Phe         275           #       280           #       285 Cys Ala Ile Pro Gln Val Met Ala Ile Ala Th #r Leu Ala Ala Cys Tyr     290               #   295               #   300 Asn Asn Gln Gln Val Phe Lys Gly Ala Val Ly #s Ile Arg Lys Gly Gln 305                 3 #10                 3 #15                 3 #20 Ala Val Thr Leu Met Met Asp Ala Thr Asn Me #t Pro Ala Val Lys Ala                 325   #               330   #               335 Ile Ile Tyr Gln Tyr Met Glu Glu Ile Tyr Hi #s Arg Ile Pro Asp Ser             340       #           345       #           350 Asp Pro Ser Ser Ser Lys Thr Arg Gln Ile Il #e Ser Thr Ile Arg Thr         355           #       360           #       365 Gln Asn Leu Pro Asn Cys Gln Leu Ile Ser Ar #g Ser His Tyr Ser Pro     370               #   375               #   380 Ile Tyr Leu Ser Phe Val Met Leu Leu Ala Al #a Leu Ser Trp Gln Tyr 385                 3 #90                 3 #95                 4 #00 Leu Ala Thr Leu Ser Gln Val Thr Glu Asp Ty #r Val Gln Thr Gly Glu                 405   #               410   #               415 His 

That which is claimed is:
 1. An isolated nucleic acid molecule encoding a squalene synthase, wherein the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of (a) a nucleotide sequence that encodes SEQ ID NO:2, except that residue 45 of SEQ ID NO:2 is arginine; (b) a nucleotide sequence that encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; (c) a nucleotide sequence having at least 95% sequence identity to SEQ ID NO:1; and (d) a nucleotide sequence having at least 95% sequence identity to SEQ ID NO:3.
 2. An isolated nucleic acid molecule consisting of a nucleotide sequence that is completely complementary to a nucleotide sequence of claim
 1. 3. A nucleic acid vector comprising the nucleic acid molecule of claim
 1. 4. The vector of claim 3, wherein said vector is selected from the group consisting of a plasmid, a virus, and a bacteriophage.
 5. The vector of claim 3, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that a polypeptide having at least 95% sequence identity to SEQ ID NO:2 may be expressed by a cell transformed wit said vector.
 6. The vector of claim 5, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.
 7. A host cell containing the vector of claim
 3. 8. A process for producing a polypeptide comprising culturing the host cell of claim 7 under conditions sufficient for the production of the polypeptide encoded by the vector, and recovering said polypeptide.
 9. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a cDNA sequence that encodes SEQ ID NO:2; (b) SEQ ID NO:1; (c) nucleotides 58-1179 of SEQ ID NO:1; and (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of any of (a)-(c).
 10. A nucleic acid vector comprising the nucleic acid molecule of claim
 9. 11. The vector of claim 10, wherein said vector is selected from the group consisting of a plasmid, a virus, and a bacteriophage.
 12. The vector of claim 10, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that a polypeptide comprising SEQ ID NO:2 may be expressed by a cell transformed with said vector.
 13. The vector of claim 12, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.
 14. A host cell containing the vector of claim
 10. 15. A process for producing a polypeptide comprising culturing the host cell of claim 14 under conditions sufficient for the production of the polypeptide encoded by the vector, and recovering said polypeptide.
 16. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence tat encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; (b) a nucleotide sequence consisting of SEQ ID NO:1; (c) a nucleotide sequence consisting of SEQ ID NO:3; and (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of any of (a)-(c).
 17. An isolated polynucleotide consisting of the nucleotide sequence of SEQ ID NO:1.
 18. An isolated polynucleotide consisting of the nucleotide sequence of SEQ ID NO:3.
 19. A nucleic acid vector comprising the nucleic acid molecule of claim
 16. 20. The vector of claim 19, wherein said vector is selected from the group consisting of a plasmid, a virus, and a bacteriophage.
 21. The vector of claim 19, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that a polypeptide comprising SEQ ID NO:2 may be expressed by a cell transformed with said vector.
 22. The vector of claim 21, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.
 23. A host cell containing the vector of claim
 19. 24. A process for producing a polypeptide comprising culturing the host cell of claim 23 under conditions sufficient for the production of the polypeptide encoded by the vector, and recovering said polypeptide. 